Therapeutic Area

Antibiotic

Therapeutic area intelligence for Antibiotic with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

RegulatoryJune 21, 2026

The FDA has granted abbreviated approval (AP) status for the ANDA064050 application for Clindamycin Phosphate submitted by Padagis US.

StrategyJune 21, 2026

Aurobindo Pharma's ANDA213568 for Cephalexin has received FDA approval.

RegulatoryJune 21, 2026

The FDA has approved Linezolid in Sodium Chloride 0.9% in a plastic container under NDA206473.

RegulatoryJune 21, 2026

The FDA has approved supplemental applications for ZYVOX (linezolid), indicating ongoing support for this antibiotic.

RegulatoryJune 21, 2026

The FDA has approved a supplemental application for Vancomycin Hydrochloride in a plastic container by Baxter Healthcare.

RegulatoryJune 19, 2026

The FDA has approved the first oral carbapenem therapy specifically for complicated urinary tract infections.

RegulatoryJune 18, 2026

Lupin's Abbreviated New Drug Application (ANDA204234) for Doxycycline has received an Approved Pending (AP) status from the FDA.

RegulatoryJune 7, 2026

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of Doxycycline Hyclate submitted by Impax Labs.

No catalysts indexed for this entity yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.